Esprit Pharma acquires rights to Estrasorb

By Angela McDaniels

Seattle, Oct. 18 - Esprit Pharma, Inc. said it has acquired exclusive North American rights to Estrasorb estradiol topical emulsion from Novavax, Inc.

The drug uses Novavax's micellar nanoparticle platform to deliver hormones through the skin to treat vasomotor symptoms (hot flashes) associated with menopause.

Esprit chairman and chief executive officer John T. Spitznagel said the action is the beginning of a strategic relationship with Novavax, with which his company will work to expand its product pipeline.

Financial terms of the announced transaction were not disclosed.

Esprit is based in New Brunswick, N.J., and focuses on the development of genito-urinary and women's health products.

Novavax is a biopharmaceutical company based in Malvern, Pa., that specializes in the drug delivery and biological technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.